title: [Comparative studies on activities of antimicrobial agents against causative organisms isolated from patients with urinary tract infections (2002). III. Secular changes in susceptibility].
abstract: The bacteria (Staphylococcus aureus, Enterococcus faecalis, Escherichia coli, Klebsiella spp. and Pseudomonas aeruginosa) isolated from patients diagnosed as urinary tract infections (UTIs) in 13 institutions in Japan were supplied between August 2002 and July 2003. The susceptibilities of these bacteria to various antimicrobial agents were examined. The bacteria were divided into 2 groups consisting of uncomplicated UTIs and complicated UTIs (with and without indwelling catheter) based on their isolation origins. The results were compared with those obtained between 1993 and 2001. The drug sensitivity of S. aureus in this year was similar to those in up to the previous year and S. aureus showed the best susceptibility to vancomycin. The drug sensitivity of E. faecalis in this year also was similar to those in up to the previous year. The drug sensitivity of E. coli in this year was generally good except penicillins and was similar to those in up to the previous year. Among cephems, cefozopran (CZOP) and cefpirome (CPR) showed the highest potency (MIC90: < or = 0.125 microg/mL). An antibacterial activity of cefotiam (CTM) was similar to it in 10 years ago and was fine (MIC90: < or = 1 microg/mL). The sensitivity of E. coli to carbapenems and carumonam (CRMN) also was good like to CZOP. However, the sensitivity of the complicated UTIs group to quinolones decreased after 2000 and was suggested to develop the resistance to the drug. The drug sensitivity of Klebsiella spp. in this year also was similar to those in up to the previous year. The bacteria showed good susceptibility (MIC: < or = 0.125 microg/mL) to cefmenoxime (CMX), CPR, cefixime (CFIX), flomoxef (FMOX), and CZOP among cephems. The drug sensitivity of P. aeruginosa was generally low. Most of the bacteria were little sensitive to cephems except CZOP and ceftazidime (CAZ). The sensitive bacteria to CZOP and ceftazidime (CAZ) were observed to be 26.8% (15/56 strains) and 39.3% (22/56 strains) in complicated UTIs group, respectively. The sensitivity profile of P. aeruginosa to the other tested drugs was not much different from that in up to the previous year. However, the sensitivity of the bacteria to carbapenems tended to decrease after 2000, and the low sensitive strains (MIC: > or = 256 microg/mL) were detected at 22.2% (2/9 strains) in the uncomplicated UTIs group and 3.6% (2/56 strains) in the complicated UTIs group.
authors.affiliation: Department of Urology, Sapporo Medical University School of Medicine.
authors.forename: Yoshiaki
authors.initials: Y
authors.lastname: Kumamoto
authors.forename: Taiji
authors.initials: T
authors.lastname: Tsukamoto
authors.forename: Masanori
authors.initials: M
authors.lastname: Matsukawa
authors.forename: Yasuharu
authors.initials: Y
authors.lastname: Kunishima
authors.forename: Takaoki
authors.initials: T
authors.lastname: Hirose
authors.forename: Osamu
authors.initials: O
authors.lastname: Yamaguti
authors.forename: Kei
authors.initials: K
authors.lastname: Ishibashi
authors.forename: Shiro
authors.initials: S
authors.lastname: Shigeta
authors.forename: Tatsuo
authors.initials: T
authors.lastname: Suzutani
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Yoshida
authors.forename: Yuuji
authors.initials: Y
authors.lastname: Imafuku
authors.forename: Masaru
authors.initials: M
authors.lastname: Murai
authors.forename: Kiyoaki
authors.initials: K
authors.lastname: Watanabe
authors.forename: Yoshio
authors.initials: Y
authors.lastname: Kobayashi
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Uchida
authors.forename: Seiji
authors.initials: S
authors.lastname: Matsuda
authors.forename: Shinichi
authors.initials: S
authors.lastname: Sato
authors.forename: Makoto
authors.initials: M
authors.lastname: Fujime
authors.forename: Kazuhiko
authors.initials: K
authors.lastname: Fujita
authors.forename: Jun
authors.initials: J
authors.lastname: Igari
authors.forename: Toyoko
authors.initials: T
authors.lastname: Oguri
authors.forename: Keizo
authors.initials: K
authors.lastname: Yamaguchi
authors.forename: Nobuhiko
authors.initials: N
authors.lastname: Furuya
authors.forename: Takashi
authors.initials: T
authors.lastname: Deguchi
authors.forename: Satoshi
authors.initials: S
authors.lastname: Ishihara
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Ooe
authors.forename: Mineko
authors.initials: M
authors.lastname: Nishikawa
authors.forename: Toshitsugu
authors.initials: T
authors.lastname: Oka
authors.forename: Masaya
authors.initials: M
authors.lastname: Kitamura
authors.forename: Yoshinori
authors.initials: Y
authors.lastname: Fukuhara
authors.forename: Sadao
authors.initials: S
authors.lastname: Kamidono
authors.forename: Soichi
authors.initials: S
authors.lastname: Arakawa
authors.forename: Hiromi
authors.initials: H
authors.lastname: Kumon
authors.forename: Koichi
authors.initials: K
authors.lastname: Monden
authors.forename: Tetsuro
authors.initials: T
authors.lastname: Matsumoto
authors.forename: Koichi
authors.initials: K
authors.lastname: Takahashi
authors.forename: Seiji
authors.initials: S
authors.lastname: Naito
authors.forename: Toshihisa
authors.initials: T
authors.lastname: Egashira
authors.forename: Shigeru
authors.initials: S
authors.lastname: Kohno
authors.forename: Yoshitsugu
authors.initials: Y
authors.lastname: Miyazaki
authors.forename: Yoichi
authors.initials: Y
authors.lastname: Hirakata
authors.forename: Siho
authors.initials: S
authors.lastname: Aoki
mesh_terms: D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D004304:Dosage Forms; D024881:Drug Resistance, Bacterial; D013293:Enterococcus faecalis / Q000187:drug effects* / Q000302:isolation & purification*; D004926:Escherichia coli / Q000187:drug effects* / Q000302:isolation & purification*; D006801:Humans; D007709:Klebsiella / Q000187:drug effects* / Q000302:isolation & purification*; D011550:Pseudomonas aeruginosa / Q000187:drug effects* / Q000302:isolation & purification*; D013211:Staphylococcus aureus / Q000187:drug effects* / Q000302:isolation & purification*; D013997:Time Factors; D014552:Urinary Tract Infections / Q000382:microbiology*
chemical_list: D000900:Anti-Bacterial Agents; D004304:Dosage Forms